Literature DB >> 22336975

Analysis of prognostic factors for patients with chordoma with use of the California Cancer Registry.

Joe Lee1, Nitin N Bhatia, Bang H Hoang, Argyrios Ziogas, Jason A Zell.   

Abstract

BACKGROUND: Chordoma is the most common primary malignant tumor of the spine. It is extremely rare and has been studied primarily in single-institution case series. Using data from a large, population-based cancer registry, we designed the present study to examine the outcome for patients with chordoma and to determine relevant prognostic factors.
METHODS: A retrospective analysis of the California Cancer Registry database was performed to identify patients with a diagnosis of chordoma in the years 1989 to 2007. Comparisons examined differences in demographics, disease characteristics, treatment, and survival. Survival analyses were performed with use of the Kaplan-Meier method with log-rank tests and Cox proportional hazards models.
RESULTS: Four hundred and nine patients with chordoma were identified; 257 (62.8%) were male and 152 (37.2%) were female. With regard to racial or ethnic distribution, 266 patients (65%) were white; ninety-three (22.7%), Hispanic; forty-three (10.5%), Asian or other; and seven (1.7%), black. The site of presentation was the head in 202 patients (49.4%), spine in 106 patients (25.9%), and pelvis and/or sacrum in 101 patients (24.7%). Hispanic race (p = 0.0002), younger age (less than forty years; p < 0.0001), and female sex (p = 0.009) were associated with cranial presentation, whereas older age (forty years or older; p < 0.0001) was associated with pelvic presentation. After adjustment for clinically relevant factors, a significantly decreased risk of death for chordoma-specific survival was seen for Hispanic race (hazard ratio = 0.51, 95% confidence interval [95% CI], 0.28 to 0.93; p = 0.03), high socioeconomic status (hazard ratio = 0.8, 95% CI, 0.67 to 0.95; p = 0.01), and local excision and/or debulking (hazard ratio = 0.38, 95% CI, 0.18 to 0.81; p = 0.01). Large tumor size was independently associated with an increased risk of death (hazard ratio = 2.05, 95% CI, 1.01 to 4.20; p = 0.048).
CONCLUSIONS: In this study, the survival of patients with chordoma was significantly better for those who were Hispanic and had a small tumor, high socioeconomic status, and surgical intervention.

Entities:  

Mesh:

Year:  2012        PMID: 22336975     DOI: 10.2106/JBJS.J.01784

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  12 in total

1.  Whole-transcriptome analysis of chordoma of the skull base.

Authors:  Diana Bell; Shaan M Raza; Achim H Bell; Gregory N Fuller; Franco DeMonte
Journal:  Virchows Arch       Date:  2016-07-11       Impact factor: 4.064

2.  Familial chordoma: A case report and review of the literature.

Authors:  K E Wang; Zhen Wu; Kaibing Tian; Liang Wang; Shuyu Hao; Liwei Zhang; Junting Zhang
Journal:  Oncol Lett       Date:  2015-09-09       Impact factor: 2.967

3.  Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival.

Authors:  Chetan Bettegowda; Stephen Yip; Sheng-Fu Larry Lo; Charles G Fisher; Stefano Boriani; Laurence D Rhines; Joanna Y Wang; Aron Lazary; Marco Gambarotti; Wei-Lien Wang; Alessandro Luzzati; Mark B Dekutoski; Mark H Bilsky; Dean Chou; Michael G Fehlings; Edward F McCarthy; Nasir A Quraishi; Jeremy J Reynolds; Daniel M Sciubba; Richard P Williams; Jean-Paul Wolinsky; Patricia L Zadnik; Ming Zhang; Niccole M Germscheid; Vasiliki Kalampoki; Peter Pal Varga; Ziya L Gokaslan
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

4.  WRN Cys1367Arg polymorphism is not associated with skull base chordoma.

Authors:  Ke Wang; Liang Wang; Jie Feng; Shuyu Hao; Kaibing Tian; Zhen Wu; Liwei Zhang; Guijun Jia; Hong Wan; Junting Zhang
Journal:  Biomed Rep       Date:  2014-05-15

5.  Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.

Authors:  Ke Wang; Kaibing Tian; Liang Wang; Zhen Wu; Cong Ren; Shuyu Hao; Jie Feng; Junhua Li; Hong Wan; Guijun Jia; Liwei Zhang; Junting Zhang
Journal:  Mol Med Rep       Date:  2015-06-22       Impact factor: 2.952

Review 6.  Chordoma dedifferentiation after proton beam therapy: a case report and review of the literature.

Authors:  Joseph Frankl; Cassi Grotepas; Baldassare Stea; G Michael Lemole; Alexander Chiu; Rihan Khan
Journal:  J Med Case Rep       Date:  2016-10-12

7.  Symptom burden and life challenges reported by adult chordoma patients and their caregivers.

Authors:  Paula H Song; Hadi Beyhaghi; Josh Sommer; Antonia V Bennett
Journal:  Qual Life Res       Date:  2017-03-17       Impact factor: 4.147

8.  Use of gluteus maximus adipomuscular sliding flaps in the reconstruction of sacral defects after tumor resection.

Authors:  Yao Weitao; Cai Qiqing; Gao Songtao; Wang Jiaqiang
Journal:  World J Surg Oncol       Date:  2013-05-23       Impact factor: 2.754

Review 9.  From notochord formation to hereditary chordoma: the many roles of Brachyury.

Authors:  Yutaka Nibu; Diana S José-Edwards; Anna Di Gregorio
Journal:  Biomed Res Int       Date:  2013-03-31       Impact factor: 3.411

10.  C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum--a single center pilot study.

Authors:  Gerhard Martin Hobusch; Florian Bodner; Sonja Walzer; Rodrig Marculescu; Philipp T Funovics; Irene Sulzbacher; Reinhard Windhager; Joannis Panotopoulos
Journal:  World J Surg Oncol       Date:  2016-04-18       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.